Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Down 40.7% in April

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totaling 586,422 shares, a decline of 40.7% from the April 15th total of 988,346 shares. Based on an average trading volume of 189,024 shares, the days-to-cover ratio is presently 3.1 days. Currently, 5.9% of the company’s shares are short sold.

Cocrystal Pharma Trading Down 4.8%

COCP traded down $0.06 during trading on Friday, reaching $1.20. 101,244 shares of the company’s stock were exchanged, compared to its average volume of 150,678. Cocrystal Pharma has a one year low of $0.86 and a one year high of $2.67. The stock has a market capitalization of $16.55 million, a PE ratio of -1.64 and a beta of 1.50. The firm has a fifty day moving average price of $1.27 and a two-hundred day moving average price of $1.11.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Thursday, May 21st. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.22 million for the quarter. Sell-side analysts expect that Cocrystal Pharma will post -0.67 earnings per share for the current year.

Institutional Investors Weigh In On Cocrystal Pharma

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 6.72% of the company’s stock.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.